The first patient has been dosed in a P-I open-label, first-in-human dose escalation study (AFM28-101) evaluating the safety, tolerability, PK & PD of AFM28 monotx. in patients with CD123+ r/r AML
The purpose of the study is to establish the MTD & one or more RP2D. Additionally, NK cells are efficiently directed by AFM28 to CD123+ leukemic cells, incl. blasts & leukemic stem & progenitor cells resulting in their depletion in samples from patients with AML & MDS
AFM28 is a tetravalent bispecific CD123- and CD16A-binding innate cell engager (ICE) that has been developed from Affimed’s Redirected Optimized Cell Killing platform. The company also plans to develop AFM28 in combination with allogeneic NK cell therapy
Ref: Affimed | Image: Affimed
Related News:- Affimed Formed a Research Collaboration with Genentech for Novel NK Cells
